Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.

Link to article at PubMed

Related Articles

Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.

Clin J Am Soc Nephrol. 2012 Oct;7(10):1722-9

Authors: Rosner MH, Dalkin AC

Abstract

Hypercalcemia complicates the course of 10%-30% of all patients with malignancies and can be a sign of very poor prognosis and advanced malignancy. Prompt recognition of the nonspecific signs and symptoms of hypercalcemia and institution of therapy can be lifesaving, affording the opportunity to address the underlying etiology. The mechanisms of malignancy-associated hypercalcemia generally fall into three categories: humoral hypercalcemia due to secreted factors (such as parathyroid-related hormone), local osteolysis due to tumor invasion of bone, and absorptive hypercalcemia due to excess vitamin D produced by malignancies. The mainstays of therapy for hypercalcemia are aggressive intravenous volume expansion with saline, bisphosphonate therapy, and perhaps loop diuretics. Adjunctive therapy may include calcitonin and corticosteroids. In refractory cases, gallium nitrate and perhaps denosumab are alternatives. In patients presenting with severe AKI, hemodialysis with a low-calcium bath can be effective. In most cases, therapy normalizes calcium levels and allows for palliation or curative therapy of the malignancy.

PMID: 22879438 [PubMed - indexed for MEDLINE]

Leave a Reply

Your email address will not be published. Required fields are marked *